Hemophilus influenzae infections: part II.
D000328:Adult; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001168:Arthritis / Q000209:etiology; D001982:Bronchial Diseases / Q000209:etiology; D002481:Cellulitis / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D003440:Croup / Q000209:etiology; D004653:Empyema / Q000209:etiology; D004697:Endocarditis, Bacterial / Q000209:etiology; D004825:Epiglottis; D006192:Haemophilus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality / Q000628:therapy; D006193:Haemophilus influenzae / Q000302:isolation & purification; D006801:Humans; D007114:Immunization; D007223:Infant; D007231:Infant, Newborn; D007827:Laryngitis / Q000209:etiology; D008297:Male; D008583:Meningitis, Haemophilus / Q000134:cerebrospinal fluid / Q000209:etiology; D010019:Osteomyelitis / Q000209:etiology; D010033:Otitis Media / Q000209:etiology; D010493:Pericarditis / Q000209:etiology; D011014:Pneumonia / Q000209:etiology; D011379:Prognosis; D018805:Sepsis / Q000209:etiology; D012852:Sinusitis / Q000209:etiology; D014481:United States
D000900:Anti-Bacterial Agents